Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lishu Zheng has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dual‐Mode CRISPR/Cas13a Assay for the Detection of Human Metapneumovirus in Clinical Respiratory Samples

    by Shiyuan Zheng, Chao Wang, Yiman Huang, Xiaocao Meng, Dong Zhao, Enrui Guan, Fenlian Ma, Aijun Chen, Lishu Zheng

    Human metapneumovirus (HMPV) is a significant pathogen, causing widespread acute respiratory infections (ARIs). Rapid and accurate detection is crucial for timely diagnosis and outbreak control. To address the limitations of real‐time reverse transcription quantitative polymerase chain reaction (RT‐qPCR)‐based HMPV detection, we developed a novel method integrating recombinase‐aided amplification (RAA) with CRISPR‐Cas13a technology. Based on the alignment of 335 HMPV whole‐genome sequences, a conserved region of the nucleocapsid ( N ) gene was selected for RAA primer and CRISPR RNA (crRNA) design. The concentrations of Cas protein, crRNA, and probe were optimized for specificity, sensitivity, and repeatability. A dual‐mode platform was established, combining a fluorescence assay for quantitative detection and a lateral flow assay (LFA) for visual, on‐site readout. Both methods were validated using 106 clinical samples and compared with RT‐qPCR. Both methods demonstrated high specificity (no cross‐reactivity with other respiratory viruses), a detection limit of 1 copy/μL, and excellent repeatability. Clinical validation showed complete concordance ( κ = 1, p < 0.001) between the fluorescence assay and RT‐qPCR, and high agreement for LFA ( κ = 0.924, p < 0.001), with a sensitivity of 94.23%, specificity of 98.15%, positive predictive value (PPV) of 98%, and negative predictive value (NPV) of 94.6%. This study presents an RAA‐CRISPR/Cas13a dual‐mode platform for HMPV detection, providing a robust molecular diagnostic framework that paves the way for the future development of rapid testing assays.


  • Open Access

    SEC11A identified as a critical host factor for HMPV through virus-induced alternative splicing

    by Yiman Huang, Jiayin Guo, Shiyuan Zheng, Aijun Chen, Lihong Yao, Ke Zhang, Lishu Zheng


  • Cytopathic Effect and Morphogenesis of WUPyV in Human Airway Epithelial Cells

    by Yiman Huang, Chao Wang, Aijun Chen, Saizhen Zeng, Xiaocao Meng, Shiyuan Fan, Jingdong Song, Lishu Zheng

    Washington University polyomavirus (WUPyV), a member of the polyomavirus family capable of infecting the human respiratory tract, exhibits high prevalence in human populations. However, confirmation of its pathogenicity and aetiology has been hindered by challenging culture conditions. To investigate the infective endocytosis of WUPyV, a novel infection model was developed using human airway organoids (HAOs); viral replication dynamics, cell tropism, endocytosis mechanisms, and morphogenesis in human airway epithelium (HAE) were characterized. The results indicated that WUPyV replicates efficiently and infects multiple cell types within the respiratory epithelium. After JC polyomavirus, WUPyV is the second human polyomavirus known to enter cells via clathrin‐mediated endocytosis, independent of caveolar/lipid raft‐mediated endocytosis or macropinocytosis. Consistent with other polyomaviruses, WUPyV is transported to the nucleus for replication and assembly through a lipid‐dependent pathway requiring tyrosine kinase activity and endosome/lysosome acidification. Assembled viral particles were observed in nuclear pores; they were ultimately released extracellularly through vesicles and schistocytes. High‐titre WUPyV infection caused extensive structural damage to the HAE and its cilia. Our findings provide important insights into the endocytosis, morphogenesis, and ultrastructural damage induced by WUPyV, supporting the notion that WUPyV is an underestimated human pathogen.

  • IFN‐α2b Modulates GATA3 Expression to Inhibit Proliferation and Promote Apoptosis in KSHV‐Infected Cells

    by Wumei Yuan, Jun Zheng, Lishu Zheng, Yifei Yue, Junjie Wan, Haojie Wang, Kaiwen Yang, Liwen Xue, Minggui Chen, Yan Zeng

    Previous studies have established that interferon (IFN) can inhibit the occurrence and progression of various tumors, particularly those associated with viral infections. However, the specific molecular mechanisms underlying its effects remain a key research focus. This study aims to elucidate how interferon inhibits Kaposi's sarcoma (KS), ultimately to improve its therapeutic efficacy against this condition. The role of IFN‐α2b in treatingKS has been extensively studied, especially regarding its antiviral properties and immune regulatory functions. In this study, we demonstrate that IFN‐α2b suppresses LANA expression in KSHV‐infected cells, thereby reducing cell proliferation and increasing apoptosis. Further investigation into the molecular mechanisms revealed that IFN‐α2b enhances the expression of GATA3, and that overexpression of GATA3 inhibits the phosphorylation of STAT5B. In summary, IFN‐α2b exerts its inhibitory effects on KS by regulating GATA3 expression. Additionally, exploring the interactions between IFN‐α2b and other molecules may uncover more complex tumor‐suppressing mechanisms.


  • Synthetic Bacterial Membrane Vesicles as Versatile Antigen-Display Platforms against Respiratory Syncytial Virus

    by Xiaocao Meng, Hanchun Gao, Qian Zhang, Fenlian Ma, Yiman Huang, Chao Wang, Shiyuan Zheng, Jingdong Song, Lishu Zheng

    Bacterial outer membrane vesicles (OMV) hold promise as vaccine platforms due to their natural adjuvant properties and nanoscale dimensions. However, their inherent inflammatory properties can induce excessive immune reactions, potentially harming the host, while their variability in size and low yield pose challenges for large-scale applications. To address these challenges, we developed synthetic bacterial vesicles (SyBV) through bacterial cell lysis followed by detergent treatment and sonication to eliminate nucleic acids, producing high-purity vesicles with minimal cytoplasmic residue. SyBV triggered comparable antigen-specific adaptive immunity but avoided strong inflammatory responses. We engineered SyBV to display the prefusion F protein (preF) of respiratory syncytial virus (RSV) with cytotoxic lysin A (ClyA). This approach effectively induced preF-specific antibodies and robust immune responses. Our findings suggest that SyBV could provide a safer, more efficient vaccine platform for preventing viral infections, overcoming the limitations associated with traditional OMV while preserving immunogenicity.


  • Open Access

    Fumarprotocetraric acid and geraniin were identified as novel inhibitors of human respiratory syncytial virus infection in vitro

    by Chao Wang, Yi-Man Huang, Jun Zhao, Yi-Ming Bai, Cai-Qin Yan, Guan-Hua Du, Li-Shu Zheng, Ai-Lin Liu

    Introduction: Respiratory syncytial virus (RSV) remains a major international public health concern. However, disease treatment is limited to preventive care with monoclonal antibodies and supportive care. In this study, natural products were screened to identify novel anti-RSV inhibitors.Methods: The antiviral effect of 320 compounds on RSV in HEp-2 cells was tested using a Cytopathic effect (CPE) inhibition assay. The antiviral effect of fumarprotocetraric acid (FUM) and geraniin (GE) were confirmed by Real-time reverse transcription quantitative PCR (Real-time RT-PCR), plaque reduction test, immunofluorescence assay, and Western blot analysis. Real-time PCR was used to detect inflammatory factor expression. ATP assay and JC-1 stain were used to evaluate mitochondrial protection function. The experiment of administration time was used to determine the stages in the RSV life cycle inhibited by FUM and GE. Human metapneumovirus (HMPV) and human rhinovirus (HRV) were used to evaluate the antiviral activities of other respiratory viruses of FUM and GE. Finally, Air-liquid interface human airway epithelium (ALI-HAE) cells were used to evaluate the antiviral effect and mechanism of FUM and GE to RSV.Results: The results showed that FUM and GE can inhibit the replication of RSV in multiple-cell models. Both compounds could dose-dependent inhibit the viral load, RSV nucleic acids level, and RSV-F protein level. Besides, FUM and GE showed good anti-inflammatory activity, mitochondrial protection, and antiviral activity to HMPV and HRV. Meanwhile, our result indicated that FUM and GE can inhibit RSV replication in ALI-HAE cells.Conclusions: FUM and GE were identified as new inhibitors of RSV infection. At the same time, FUM and GE have anti-inflammatory activity, mitochondrial protection function, and broad-spectrum antiviral activity. These results provide evidence that FUM and GE are potential candidates for the development of novel anti-RSV drugs.


  • Open Access

    Immunogenicity and protective efficacy of human metapneumovirus virus-like particles produced by a recombinant baculovirus in mice

    by Fenlian Ma, Aijun Chen, Lihong Yao, Hanchun Gao, Qian Zhang, Wenzhe Hou, Lishu Zheng


  • Open Access

    Systems pharmacology dissection of pharmacological mechanisms of Xiaochaihu decoction against human coronavirus

    by Lvjie Xu, Chuipu Cai, Jiansong Fang, Qihui Wu, Jun Zhao, Zhe Wang, Pengfei Guo, Lishu Zheng, Ailin Liu

    Background: Although coronavirus disease 2019 (COVID-19) pandemic is still rage worldwide, there are still very limited treatments for human coronaviruses (HCoVs) infections. Xiaochahu decoction (XCHD), which is one of the traditional Chinese medicine (TCM) prescriptions in Qingfeipaidu decoction (QFPDD), is widely used for COVID-19 treatment in China and able to relieve the symptoms of fever, fatigue, anorexia, and sore throat. To explore the role and mechanisms of XCHD against HCoVs, we presented an integrated systems pharmacology framework in this study. Methods: We constructed a global herb-compound-target (H-C-T) network of XCHD against HCoVs. Multi-level systems pharmacology analyses were conducted to highlight the key XCHD-regulated proteins, and reveal multiple HCoVs relevant biological functions affected by XCHD. We further utilized network-based prediction, drug-likeness analysis, combining with literature investigations to uncover the key ani-HCoV constituents in XCHD, whose effects on anit-HCoV-229E virus were validated using cytopathic effect (CPE) assay. Finally, we proposed potential molecular mechanisms of these compounds against HCoVs via subnetwork analysis. Results: Based on the systems pharmacology framework, we identified 161 XCHD-derived compounds interacting with 37 HCoV-associated proteins. An integrated pathway analysis revealed that the mechanism of XCHD against HCoVs is related to TLR signaling pathway, RIG-I-like receptor signaling pathway, cytoplasmic DNA sensing pathway, and IL-6/STAT3 pro-inflammatory signaling pathway. Five compounds from XCHD, including betulinic acid, chrysin, isoliquiritigenin, schisandrin B, and (20R)-Ginsenoside Rh1 exerted inhibitory activity against HCoV-229E virus in Huh7 cells using in vitro CPE assay. Conclusion: Our work presented a comprehensive systems pharmacology approach to identify the effective molecules and explore the molecular mechanism of XCHD against HCoVs.


  • Whole genome sequencing and evolution analyses of Human metapneumovirus

    by Tianli Wei, Chao Wang, Fenlian Ma, Jianqiang Guo, Aijun Chen, Yiman Huang, Zhiping Xie, Lishu Zheng

    Human metapneumovirus (HMPV) is a major pathogen of acute respiratory tract infections (ARTIs) in children. Whole genome sequence analyses could help understand the evolution and transmission events of this virus. In this study, we sequenced HMPV whole genomes to improve the identification of molecular epidemiology in Beijing, China. Nasopharyngeal aspirates of hospitalized children aged < 14 years old with ARTIs were screened for HMPV infection using qPCR. Fourteen pairs of overlapping primers were used to amplify whole genome sequences of HMPV from positive samples with high viral loads. The epidemiology of HMPV was analysed and 27 HMPV whole genome sequences were obtained. Sequence identity and the positional entropy analyses showed that most regions of HMPV genome are conserved, whereas the G gene contained many variations. Phylogenetic analysis identified 25 HMPV sequences that belonged to a newly defined subtype A2b1; G gene sequences from 24 of these contained a 111-nucleotide duplication. HMPV is an important respiratory pathogen in paediatric patients. The new subtype A2b1 with a 111-nucleotide duplication has become predominate in Beijing, China.


  • Establishment of a neutralization assay for Nipah virus using a high-titer pseudovirus system

    by Xiaoyi Luo, Chao Wang, Yiman Huang, Shanshan Cong, Jingjing Tan, Wenzhe Hou, Fenlian Ma, Lishu Zheng

    Objective To construct a high-titer Nipah pseudovirus packaging system using the HIV lentivirus backbone vector and establish a safe neutralization assay for Nipah pseudovirus in biosafety level 2 facilities. Methods Nipah virus (NiV) fusion protein (F) and glycoprotein (G) recombinant expression plasmids, psPAX2, and pLenti CMV Puro LUC (w168-1) were transiently transfected into 293T cells for 72 h for the generation of a NiV pseudovirus. The neutralization ability of Nipah virus F and G protein antibodies was assessed using the pseudovirus. Results A NiV pseudovirus was constructed using 293T cells. The ideal mass ratio of plasmid psPAX2: w168-1: F: G for transfection was determined to be 4:4:1:1. The specificity of recombinant F and G protein expression was indicated by indirect immunofluorescence and western blotting. The pseudovirus particles showed obvious spikes under a transmission electron microscope. The NiV pseudovirus titer was 4.73 × 105 median tissue culture infective dose per mL, and the pseudovirus could be effectively neutralized by polyclonal antibodies specifically targeting the F and G proteins respectively. Conclusions A NiV pseudovirus was successfully generated using HIV vector systems, and was used as a platform for a safe and reliable pseudovirus-based neutralizing assay that can be performed in biosafety level 2 facilities.